Your session is about to expire
← Back to Search
TSPO Radioligand PET Imaging for Neurodegenerative Disease
Study Summary
This trial is testing a drug to see if it can show brain inflammation in people with certain progressive neurological disorders compared to healthy adults, as well as finding genes associated with these disorders.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You are 18 or older, able to give permission in writing, and have a family history or other risk of developing an adult-onset genetic brain disease, or have a gene mutation linked to an adult-onset brain disease.You have a history of serious medical conditions, recent exposure to radiation, are pregnant or breastfeeding, have substance or alcohol use disorders, or are unable to have an MRI scan.Criterion: You have a high risk of developing serious neurological diseases, unstable medical condition, need ventilator support during the day, can't travel to NIH, had recent radiation exposure, can't lie flat or still for a long time, are pregnant or breastfeeding, have a substance or alcohol use disorder, can't have an MRI scan, or are an employee or relative of an NIH investigator.
- Group 1: PET scan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment actively seeking volunteers?
"According to the data available on clinicaltrials.gov, this experimental intervention is currently open for participants in need of treatment. The trial was first made public on July 3rd 2019 and had its most recent update posted at the end of September 2022."
How many participants can enroll in this experiment?
"Correct. According to cliniciansltrials.gov, this inquiry has been posted since July 3rd 2019 and was recently updated on September 30th 2022. The research is recruiting 200 individuals across one site."
Are there any Food and Drug Administration authorizations associated with 11C-ER176?
"Taking into account its Phase 1 classification, our team at Power assigned 11C-ER176 a score of 1 due to the scant evidence that supports both safety and efficacy."
Share this study with friends
Copy Link
Messenger